uniQure
QURE

$5.42

1.99%

Market Cap: $264M

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Employees: 480

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

149% more call options, than puts

Call options by funds: $7.81M | Put options by funds: $3.14M

0.2% more ownership

Funds ownership: 70.61% [Q1] → 70.81% (+0.2%) [Q2]

3% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 37

10% less funds holding

Funds holding: 129 [Q1] → 116 (-13) [Q2]

14% less capital invested

Capital invested by funds: $178M [Q1] → $154M (-$24.3M) [Q2]

41% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 32

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

85%

upside

Avg. target

$21

287%

upside

High target

$25

361%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	361%upside $25	Buy Reiterated	20 Aug 2024
Goldman Sachs Salveen Richter 50% 1-year accuracy 10 / 20 met price target	85%upside $10	Neutral Maintained	2 Aug 2024
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target	343%upside $24	Overweight Reiterated	16 Jul 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	361%upside $25	Buy Reiterated	9 Jul 2024

See Analyst Rankings

Financial journalist opinion

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of AMT-191 in individuals with Fabry disease.

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end.

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Zacks Investment Research

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates

UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago.

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Zacks Investment Research

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

What Led To A 150% Rise In UniQure Stock In A Week?

uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.

What Led To A 150% Rise In UniQure Stock In A Week?

Zacks Investment Research

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

Zacks Investment Research

uniQure (QURE) Soars on New Huntington's Disease Study Data

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

uniQure (QURE) Soars on New Huntington's Disease Study Data

Zacks Investment Research

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

See News Rankings